Oxford Cannabinoid Technologies Holdings Plc (OCTP.L) LSE
Currency In GBp
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In GBp
Address
Maddox House
London, W1S 2PZ
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 3034 2820
Website
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
May 21, 2021
| Name | Title | Pay | Year Born |
| Clarissa Ann Sowemimo-Coker | Chief Executive Officer & Executive Director | 215,669 | 1980 |
| Indraneil Mahapatra | Co-Founder & Non-Executive Director | 25,000 | 1980 |
| Paul William Smalley | Finance Director & Executive Director | 155,159 | 1973 |
| Timothy H. Corn | Executive Director & Chief Medical Officer | 0 | 1951 |
| Valentino Parravicini | Chief Scientific Officer | 0 | 1969 |
| Robin Bennett | General Counsel & Company Secretary | 0 | N/A |
Oxford Cannabinoid Technologies Holdings Plc operates as a pharmaceutical company, focused on the research, development, and commercialization of cannabinoid-derived prescription medications. Their principal drug candidate, OCT461201, is a selective CB2 receptor agonist in an oral solid dosage format, currently undergoing pre-clinical assessment. It is being developed to target visceral pain associated with Irritable Bowel Syndrome (IBS), as well as a range of neuropathic pain conditions, notably post-herpetic neuralgia. The company is also progressing with OCT130401, another compound in pre-clinical development, intended for the treatment of trigeminal neuralgia. Incorporated in 2017, Oxford Cannabinoid Technologies Holdings Plc is based in London, United Kingdom.